Heejae Jung, PA
Rheumatology · Honolulu, HINPI 1881249688
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 255 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,190, 2.1 times the $573 reported in 2021.
Across 255 payments — averaging $15.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$941
- UCB, Inc.$830
- Amgen$764
- Pfizer$383
- Novartis$196
- GSK$186
- plus $728 from 12 others
What the payments were for
- Food & beverage$4,027100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $941 |
| UCB, Inc. | 67 | $830 |
| Amgen | 65 | $764 |
| Pfizer | 25 | $383 |
| Novartis | 8 | $196 |
| GSK | 10 | $186 |
| Lilly USA, LLC | 8 | $183 |
| AstraZeneca | 5 | $124 |
| Aurinia Pharma U.S., Inc. | 3 | $79 |
| Bioventus LLC | 3 | $78 |
| E.r. Squibb & Sons, L.L.C. | 3 | $63 |
| Johnson & Johnson | 1 | $43 |
| Mallinckrodt Hospital Products Inc. | 1 | $32 |
| Tonix Medicines, Inc. | 1 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $32 |
| Arcutis Biotherapeutics, Inc. | 1 | $25 |
| Sobi, Inc | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
How this compares
$4,027 in reported general payments places this provider in the 65th percentile of 21 rheumatology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 98 | $7,081 |
| Celecoxib | 86 | $4,373 |
| MethotrexateMethotrexate Sodium | 86 | $3,705 |
| Raloxifene Hcl | 33 | $2,985 |
| Mycophenolate Mofetil | 17 | $2,023 |
| Gabapentin | 89 | $1,717 |
| Colchicine | 20 | $1,543 |
| Meloxicam | 157 | $1,472 |
| Prednisone | 207 | $1,470 |
| Alendronate Sodium | 43 | $1,058 |
| Atorvastatin Calcium | 17 | $824 |
| Duloxetine Hcl | 12 | $764 |
| Allopurinol | 38 | $761 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 15 | $589 |
| Diclofenac Sodium | 12 | $550 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Honolulu
- Scott KawamotoHonolulu$58K
- Daniel BrandtHonolulu$29K
- Kristine UramotoHonolulu$26K
- Deryll AmbrocioHonolulu$21K
- Mari ShiraishiHonolulu$9K
- Devy SetyonoHonolulu$9K
- Sadao JinnoHonolulu$6K
- Denny NakayamaHonolulu$3K
- Ken ArakawaHonolulu$3K
- Alberto Santos-OcampoHonolulu$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.